ArticleInternational journal of nanomedicine2018
Facile fabrication of hypericin-entrapped glyconanoparticles for targeted photodynamic therapy.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Artificial Intelligence and Natural Photosensitizer-Based Nanopharmaceuticals in Photodynamic Therapy: Advanced Modeling, Data-Driven Optimization, and Translational Perspectives.Pharmaceutics · 2026Review
- A Minireview on Nanosized Hypericin-Based Inducer of Immune Cell Death Under ROS-Based Therapies.International journal of nanomedicine · 2025Review
- In Vitro Photoselective Gene Transfection of Hepatocellular Carcinoma Cells with Hypericin Lipopolyplexes.ACS applied materials & interfaces · 2024Article
- Nanotherapeutic Intervention in Photodynamic Therapy for Cancer.ACS omega · 2022Review
- Multifunctional Nanoplatforms as a Novel Effective Approach in Photodynamic Therapy and Chemotherapy, to Overcome Multidrug Resistance in Cancer.Pharmaceutics · 2022Review
- A Supramolecular Photosensitizer System Based on Nano-Cu/ZIF-8 Capped with Water-Soluble Pillar[6]arene and Methylene Blue Host-Guest Complexations.Molecules (Basel, Switzerland) · 2021Article
- Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.Molecules (Basel, Switzerland) · 2020Review
- A Hypericin Delivery System Based on Polydopamine Coated Cerium Oxide Nanorods for Targeted Photodynamic Therapy.Polymers · 2019Article
- Polydopamine-Based Nanocarriers for Photosensitizer Delivery.Frontiers in chemistry · 2019Review
- A multifunctional supramolecular vesicle based on complex of cystamine dihydrochloride capped pillar[5]arene and galactose derivative for targeted drug delivery.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhotodynamic therapy is a safe, noninvasive modality for cancer therapy, in which the photosensitizer (PS) is a crucial component. Hypericin (Hy) is a promising PS; however, its clinical application is significantly limited by its poor hydrophilicity. MATERIALS AND
methodsTo overcome the clinical application limitation of Hy, a novel strategy is developed here by entrapping Hy into polydopamine (PDA) film formed on the surface of magnetic iron oxide nanoparticles (MNPs) through the self-polymerization of dopamine under alkaline condition. The amount of Hy in the Hy-entrapped PDA-MNP composite nanoparticles (denoted as PHMs) was measured by spectrophotometry. Furthermore, lactose, as the targeting ligand to asialoglycoprotein receptors, was conjugated to the surface of the PHMs by taking advantage of the spontaneous reaction of PDA with amino groups.
resultsSpectrophotometry analysis revealed that the amount of Hy in the PHMs was 72 μmol g
conclusionThe strategy developed in this work offers great potential for delivery of a variety of hydrophobic PSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.